Zacks Research Lowers Earnings Estimates for OPKO Health

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Analysts at Zacks Research cut their Q2 2025 EPS estimates for OPKO Health in a research report issued on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $149.90 million for the quarter, compared to analysts' expectations of $163.13 million. During the same quarter last year, the business posted ($0.12) EPS. The business's quarterly revenue was down 13.7% compared to the same quarter last year.

Several other research firms have also issued reports on OPK. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. JPMorgan Chase & Co. started coverage on OPKO Health in a research note on Friday, April 25th. They set a "neutral" rating for the company. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, May 1st. Finally, Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $2.75.

OPKO Health Trading Down 0.8%

Shares of OPKO Health stock traded down $0.01 on Monday, hitting $1.30. The stock had a trading volume of 1,768,269 shares, compared to its average volume of 3,899,709. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -6.84 and a beta of 1.42. The stock's 50-day simple moving average is $1.44 and its two-hundred day simple moving average is $1.55. OPKO Health has a one year low of $1.19 and a one year high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 67,434 shares of the business's stock in a transaction on Friday, February 28th. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the purchase, the chief executive officer now directly owns 213,301,448 shares of the company's stock, valued at approximately $364,745,476.08. This trade represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have bought 767,434 shares of company stock worth $1,238,312. Company insiders own 49.69% of the company's stock.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Oak Thistle LLC purchased a new stake in shares of OPKO Health during the first quarter worth about $26,000. GM Advisory Group LLC purchased a new stake in shares of OPKO Health during the first quarter worth approximately $33,000. Cerity Partners LLC purchased a new stake in shares of OPKO Health during the first quarter worth approximately $36,000. Pallas Capital Advisors LLC purchased a new stake in OPKO Health in the 1st quarter valued at $43,000. Finally, Voleon Capital Management LP acquired a new position in shares of OPKO Health in the 1st quarter valued at $45,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.